Cost-Effectiveness of FreeStyle Libre for Glucose Self-Management Among People with Diabetes Mellitus: A Canadian Private Payer Perspective
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
For people living with diabetes, effective glucose monitoring is a key component in diabetes care, helping to reduce disease burden, complications, and healthcare utilization. Sensor-based glucose monitoring systems, which can provide more comprehensive information about glucose levels than capillary-based self-monitoring of blood glucose (SMBG), are becoming established among people living with diabetes. The objective of this study was to assess the cost-effectiveness of glucose monitoring with FreeStyle Libre systems, compared with SMBG, from the perspective of a Canadian private payer. The analysis used the validated, person-level microsimulation model DEDUCE (Determination of Diabetes Utilities, Costs, and Effects). Analyses were conducted separately for populations of people with type 1 and type 2 diabetes mellitus (T1DM; T2DM), with time horizons of 40 and 25 years, respectively. T2DM treatment was assumed to be 84% non-insulin, 10% basal insulin, and 6% multiple daily injections of insulin. The effect of FreeStyle Libre was modeled as reductions versus SMBG in glycated hemoglobin level (T1DM, − 0.42%; insulin-treated T2DM, − 0.59%; non-insulin-treated T2DM, − 0.3%) and in acute diabetic events (hypoglycemia and diabetic ketoacidosis). Costs (in 2023 Canadian dollars (Can$)) and utilities were discounted at 1.5%. Outcomes were assessed as costs and quality-adjusted life years (QALYs). In both populations, FreeStyle Libre was dominant to SMBG, providing more QALYs at a lower cost (T1DM: + 1.25 QALYs, − Can$32,287 costs; T2DM: + 0.48 QALYs, − Can$8091 costs). Reductions were seen in the cumulative incidence of all complications (except blindness in the T1DM analysis). FreeStyle Libre was dominant to SMBG in all scenarios tested. Probabilistic sensitivity analysis showed that FreeStyle Libre had a 100% probability of being dominant to SMBG for T1DM and a 91% probability of being dominant for T2DM. This economic analysis shows that, from a Canadian private payer perspective, FreeStyle Libre is cost-effective compared with SMBG for all people living with diabetes. Glucose monitoring is important for people living with diabetes. Effective glucose monitoring can reduce the risk of hypoglycemia (low blood sugar), diabetic ketoacidosis (a potentially life-threatening complication which occurs when the body has low insulin and high blood sugar levels), and long-term complications. This can be done using finger sticks and test strips or sensor-based devices such as the FreeStyle Libre systems. In this study, we modeled the effect of FreeStyle Libre use in persons living with type 1 or type 2 diabetes mellitus in Canada using the DEDUCE economic model. In both analyses, FreeStyle Libre use was predicted to lead to better outcomes (measured as quality-adjusted life years—a measure of health which combines life expectancy with quality of life) for people living with diabetes while reducing costs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A recent Canadian economic analysis using a person‐level microsimulation model showed that isCGM is more cost‐effective than BGM. 60”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Canadian Institute for Health Information.
Lalonde, A. (1994) · PubMed · Cited by 4,739
Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities
Rodbard, D. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0417 · Cited by 737 · cited 2×
“As a result, the use of sensor-based glucose monitoring systems, which can provide more comprehensive information about glucose levels than SMBG while reducing the need for fingersticks, is becoming established among people living with diabetes [5].”
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623
The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXII
Klein, R., Knudtson, M. D., Lee, K. E., Gangnon, R., & Klein, B. E. K. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.08.023 · Cited by 584 · cited 1×
“…T1DM, complications are modeled using the Sheffield Type 1 Diabetes Model equations, which were primarily derived from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study and the Wisconsin Epidemiological Study of Diabetic Retinopathy [19–21].”
Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62)
Clarke, P., Gray, A., & Holman, R. (2002) · Medical Decision Making · doi:10.1177/027298902400448902 · Cited by 515 · cited 1×
“In the absence of Canada-specific data, baseline health utility values (0.839 for T1DM and 0.785 for T2DM) were taken from two UK prospective studies (Supplementary Material, Table S1) [25, 35, 56–64].”
InfluentialMultivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes
Currie, C. J., Morgan, C. L., Poole, C. D., Sharplin, P., Lammert, M., & McEwan, P. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x115757 · Cited by 279 · cited 1×
“For people living with T1DM, a further disutility of 0.025 was applied to those using SMBG, based on the fear of hypo-glycemia reported in a UK survey [63].”
InfluentialEdridge, C. L., Dunkley, A. J., Bodicoat, D. H., Rose, T. C., Gray, L. J., Davies, M. J., & Khunti, K. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126427 · Cited by 225 · cited 2×
“The rate of NSHE was based on published studies [14, 31, 35] and was conservatively assumed not to be reduced with FreeStyle Libre among persons living with T2DM who were not using insulin.”
Basu, S., Sussman, J. B., Berkowitz, S. A., Hayward, R. A., & Yudkin, J. S. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30221-8 · Cited by 206 · cited 4×
“The modeled population characteristics are shown in Table 1 [11, 25] and Table 2 [7, 22, 26, 27].”
InfluentialEvans, M., Welsh, Z., Ells, S., & Seibold, A. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00720-0 · Cited by 185 · cited 1×
“The use of FreeStyle Libre has been found to improve glycated hemoglobin (HbA1c) levels, reduce hypoglycemia, and increase the time spent in the recommended glycemic range [6–11].”
Obesity in people living with type 1 diabetes
Van der Schueren, B., Ellis, D., Faradji, R. N., Al-Ozairi, E., Rosen, J., & Mathieu, C. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00246-1 · Cited by 185 · cited 1×
“…an additional disutility of 0.0028 per kg/m 2 was applied to people with a body mass index above 25 kg/m 2 (based on the results of a UK prospective study [56]) in order to capture the negative impact of insulin-related weight gain, which is of particular concern for persons living with T1DM [65].”
InfluentialDeshmukh, H., Wilmot, E. G., Gregory, R., Barnes, D., Narendran, P., Saunders, S., Furlong, N., Kamaruddin, S., Banatwalla, R., Herring, R., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0738 · Cited by 175
Roussel, R., Riveline, J.-P., Vicaut, E., de Pouvourville, G., Detournay, B., Emery, C., Levrat-Guillen, F., & Guerci, B. (2021) · Diabetes Care · doi:10.2337/dc20-1690 · Cited by 173 · cited 2×
“…the T2DM non-insulin group, rates of DKA and SHE for SMBG were based on Danish real-world evidence [30] and a meta-analysis of population-based studies [31], respectively, and were assumed to be reduced with FreeStyle Libre to the same degree as in the T2DM basal insulin group in RELIEF [13, 29].”
Fokkert, M., van Dijk, P., Edens, M., Barents, E., Mollema, J., Slingerland, R., Gans, R., & Bilo, H. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000809 · Cited by 163
Pettus, J. H., Zhou, F. L., Shepherd, L., Preblick, R., Hunt, P. R., Paranjape, S., Miller, K. M., & Edelman, S. V. (2019) · Diabetes Care · doi:10.2337/dc19-0830 · Cited by 160 · cited 1×
“As in previous FreeStyle Libre models [38, 39], in the absence of specific data, mortality due to DKA and SHE was assumed to be the same with SMBG and FreeStyle Libre [32–34].”
Wada, E., Onoue, T., Kobayashi, T., Handa, T., Hayase, A., Ito, M., Furukawa, M., Okuji, T., Okada, N., Iwama, S., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001115 · Cited by 157 · cited 1×
“For persons living with T2DM not using insulin, a reduction of 0.3% versus SMBG was applied, based on the 16-week Canadian RCT IMMEDIATE [27]; this reduction versus SMBG is consistent with the results seen at week 24 in a Japanese RCT [10].”
InfluentialWright, A. D., Cull, C. A., Macleod, K. M., & Holman, R. R. (2006) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2005.08.010 · Cited by 153 · cited 1×
“As in previous FreeStyle Libre models [38, 39], in the absence of specific data, mortality due to DKA and SHE was assumed to be the same with SMBG and FreeStyle Libre [32–34].”
Return to work after lower limb amputation
Burger, H., & Marinček, Č. (2007) · Disability and Rehabilitation · doi:10.1080/09638280701320797 · Cited by 152 · cited 1×
“The proportions of persons returning to work after a stroke or amputation were taken from literature reviews [44, 45].”
Palmer, A. J., Clarke, P., Gray, A., Leal, J., Lloyd, A., Grant, D., Palmer, J., FOOS, V., Lamotte, M., Hermann, W., et al. (2013) · Value in Health · doi:10.1016/j.jval.2013.01.002 · Cited by 148 · cited 1×
“The model has been shown to perform favorably in an analysis based on previous Mount Hood challenges [67, 68], predicting key outcomes, including cardio-vascular disease in T1DM and all-cause mortality in T2DM, and performing well against other models [18].”
Cost sharing, adherence, and health outcomes in patients with diabetes.
Gibson, T. B., Song, X., Alemayehu, B., Wang, S. S., Waddell, J. L., Bouchard, J. R., & Forma, F. M. (2010) · PubMed · Cited by 141
Economic burden of illness associated with diabetic foot ulcers in Canada
Hopkins, R. B., Burke, N., Harlock, J., Jegathisawaran, J., & Goeree, R. A. (2015) · BMC Health Services Research · doi:10.1186/s12913-015-0687-5 · Cited by 140
Aronson, R., Brown, R. E., Chu, L., Bajaj, H. S., Khandwala, H., Abitbol, A., Malakieh, N., & Goldenberg, R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14949 · Cited by 118 · cited 4×
“The modeled population characteristics are shown in Table 1 [11, 25] and Table 2 [7, 22, 26, 27].”
InfluentialThe Cost of Care for People With Chronic Kidney Disease
Manns, B., Hemmelgarn, B. R., Tonelli, M. A., Au, F., So, H., Weaver, R., Quinn, A. E., Klarenbach, S. W., & Disease, F. C. S. S. A. I. T. O. C. K. (2019) · Canadian Journal of Kidney Health and Disease · doi:10.1177/2054358119835521 · Cited by 115
Ahola, A. J., Saraheimo, M., Forsblom, C. M., Hietala, K., Sintonen, H., Groop, P., & on behalf of the FinnDiane Study Group (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp709 · Cited by 94 · cited 4×
“The modeled population characteristics are shown in Table 1 [11, 25] and Table 2 [7, 22, 26, 27].”
InfluentialBergenstal, R. M., Kerr, M. S. D., Roberts, G. J., Souto, D., Nabutovsky, Y., & Hirsch, I. B. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab013 · Cited by 89 · cited 2×
“The rate of NSHE was based on published studies [14, 31, 35] and was conservatively assumed not to be reduced with FreeStyle Libre among persons living with T2DM who were not using insulin.”
Disability stigmatization as a barrier to employment equity for legally-blind Canadians
Benoit, C., Jansson, M., Jansenberger, M., & Phillips, R. (2012) · Disability & Society · doi:10.1080/09687599.2012.741518 · Cited by 84 · cited 2×
“Long-term absence was modeled based on persons living with diabetes not returning to work after diabetes complications (Table 4) [40–55].”
Shao, H., Yang, S., Fonseca, V., Stoecker, C., & Shi, L. (2019) · PharmacoEconomics · doi:10.1007/s40273-019-00775-8 · Cited by 81 · cited 1×
“Disutilities associated with complications, DKA, SHEs, and NSHEs were taken from the literature (Supplementary Material, Table S1) [25, 35, 56–61].”
Return to Work After Acute Myocardial Infarction: Comparison Between Young Women and Men
Dreyer, R. P., Xu, X., Zhang, W., Du, X., Strait, K. M., Bierlein, M., Bucholz, E. M., Geda, M., Fox, J., D’Onofrio, G., et al. (2016) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.002611 · Cited by 78 · cited 2×
“…for myocardial infarction was taken from the international (USA, Spain, and Australia) Variation In Recovery: Role of Gender on Outcomes of young acute myocardial infarction patients (VIRGO) study, which included data for 1680 people aged 18–55 years hospitalized with myocardial infarction [42].”
Manns, B., McKenzie, S. Q., Au, F., Gignac, P. M., Geller, L. I., & for the Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD) Network (2017) · Canadian Journal of Kidney Health and Disease · doi:10.1177/2054358117703986 · Cited by 75 · cited 1×
“The ability of people with renal failure to work was taken from a Canadian study which included all employed Canadians aged 40–64 years who had end-stage renal disease [43].”
Carlson, A. L., Daniel, T. D., DeSantis, A., Jabbour, S., Karslioglu French, E., Kruger, D., Miller, E., Ozer, K., & Elliott, T. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002590 · Cited by 69 · cited 3×
“The modeled population characteristics are shown in Table 1 [11, 25] and Table 2 [7, 22, 26, 27].”
Guerci, B., Roussel, R., Levrat-Guillen, F., Detournay, B., Vicaut, E., De Pouvourville, G., Emery, C., & Riveline, J.-P. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0271 · Cited by 69 · cited 3×
“…the T2DM non-insulin group, rates of DKA and SHE for SMBG were based on Danish real-world evidence [30] and a meta-analysis of population-based studies [31], respectively, and were assumed to be reduced with FreeStyle Libre to the same degree as in the T2DM basal insulin group in RELIEF [13, 29].”
Evans, M., Welsh, Z., & Seibold, A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01253-9 · Cited by 67 · cited 1×
“HbA1c was reduced by 0.42% and 0.59% for insulin-using persons living with T1DM and T2DM, respectively, based on a meta-analysis of clinical trials and real-world observational studies [28].”
InfluentialPeasgood, T., Brennan, A., Mansell, P., Elliott, J., Basarir, H., & Kruger, J. (2016) · Medical Decision Making · doi:10.1177/0272989x16658660 · Cited by 66 · cited 3×
“…an additional disutility of 0.0028 per kg/m 2 was applied to people with a body mass index above 25 kg/m 2 (based on the results of a UK prospective study [56]) in order to capture the negative impact of insulin-related weight gain, which is of particular concern for persons living with T1DM [65].”
InfluentialJendle, J., Pöhlmann, J., de Portu, S., Smith-Palmer, J., & Roze, S. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0328 · Cited by 52
Si, L., Willis, M. S., Asseburg, C., Nilsson, A., Tew, M., Clarke, P., Lamotte, M., Ramos, M., Shao, H., Shi, L., et al. (2020) · Value in Health · doi:10.1016/j.jval.2020.04.1832 · Cited by 47 · cited 1×
“The model has been shown to perform favorably in an analysis based on previous Mount Hood challenges [67, 68], predicting key outcomes, including cardio-vascular disease in T1DM and all-cause mortality in T2DM, and performing well against other models [18].”
Ward, J. E. F., Stetson, B. A., & Mokshagundam, S. P. L. (2015) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/s40200-015-0172-z · Cited by 45 · cited 1×
“However, many people living with diabetes find a capillary-based self-monitoring of blood glucose (SMBG) system painful and difficult to integrate into their daily lives [4].”
Pollard, D. J., Brennan, A., Dixon, S., Waugh, N. R., Elliott, D., Heller, S. R., Lee, E. C., Campbell, M. J., Basarir, H., & White, D. A. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-016766 · Cited by 45
Health State Utilities Associated with Glucose Monitoring Devices
Matza, L. S., Stewart, K. D., Davies, E. W., Hellmund, R., Polonsky, W. H., & Kerr, D. (2017) · Value in Health · doi:10.1016/j.jval.2016.10.007 · Cited by 44 · cited 1×
“…of blood glucose, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus Congestive heart failure 24% German real-world data; Reibis 2017 [41] Myocardial infarction 13% International real-world data; Dreyer 2016 [42] using SMBG, based on a time trade-off study conducted in the UK [62].”
Thokala, P., Kruger, J., Brennan, A., Basarir, H., Duenas, A., Pandor, A., Gillett, M., Elliott, J., & Heller, S. (2014) · Diabetic Medicine · doi:10.1111/dme.12371 · Cited by 39 · cited 1×
“…T1DM, complications are modeled using the Sheffield Type 1 Diabetes Model equations, which were primarily derived from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study and the Wisconsin Epidemiological Study of Diabetic Retinopathy [19–21].”
Jensen, M. L., Persson, F., Andersen, G. S., Ridderstråle, M., Nolan, J. J., Carstensen, B., & Jørgensen, M. E. (2017) · Diabetes Care · doi:10.2337/dc16-2793 · Cited by 38 · cited 1×
“For the T2DM non-insulin group, rates of DKA and SHE for SMBG were based on Danish real-world evidence [30] and a meta-analysis of population-based studies [31], respectively, and were assumed to be reduced with FreeStyle Libre to the same degree as in the T2DM basal insulin group in RELIEF [13,…”
Blood Glucose Monitoring in Adults and Children with Diabetes: Update 2021
CHENG, A. Y. Y., Feig, D. S., Ho, J., Siemens, R. L., BAJAJ, H. S., Gilbert, J. D., Houlden, R. L., Kim, J., MacKay, D., Rabi, D. M., et al. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.07.003 · Cited by 38
Duong, P., Sauvé-Schenk, K., Egan, M. Y., Meyer, M. J., & Morrison, T. (2019) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2018.09.121 · Cited by 36 · cited 1×
“The proportions of persons returning to work after a stroke or amputation were taken from literature reviews [44, 45].”
Bilir, S. P., Hellmund, R., Wehler, B., Li, H., Munakata, J., & Lamotte, M. (2018) · European Endocrinology · doi:10.17925/ee.2018.14.2.73 · Cited by 34 · cited 4×
“The rate of NSHE was based on published studies [14, 31, 35] and was conservatively assumed not to be reduced with FreeStyle Libre among persons living with T2DM who were not using insulin.”
InfluentialThe Healthcare Cost Burden of Acute Myocardial Infarction in Alberta, Canada
Tran, D. T., Ohinmaa, A. E., Thành, N. X., Welsh, R. C., & Kaul, P. (2017) · PharmacoEconomics - Open · doi:10.1007/s41669-017-0061-0 · Cited by 33
Roze, S., Buompensiere, M. I., Ozdemir, Z., de Portu, S., & Cohen, O. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.1939706 · Cited by 30 · cited 1×
“The Medtronic devices are often used with insulin pumps, a combination which has been found to be cost-effective compared with insulin pumps alone in studies outside Canada [71, 72].”
Frank, J., Blissett, D. B., Hellmund, R., & Virdi, N. S. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0263 · Cited by 30 · cited 2×
“Interestingly, Frank et al. found that for both T1DM and T2DM, reductions in hospital admissions were major drivers of the cost savings seen with FreeStyle Libre [76].”
Rotondi, M. A., Wong, O. C. Y., Riddell, M. C., & Perkins, B. A. (2022) · Diabetes Care · doi:10.2337/dc21-2341 · Cited by 25 · cited 2×
“…to be a cost-effective glucose monitoring sys-tem for type 1 diabetes mellitus (T1DM) when assessed from a Canadian healthcare system perspective [16], but no previous cost-effectiveness analysis has been conducted for all people living with diabetes in Canada, including those not on insulin.”
Frank, J., Son, D., Szafranski, K., & Poon, Y. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.24025 · Cited by 25 · cited 2×
“FreeStyle Libre has also been found to be cost-effective for persons living with T2DM using basal insulin in Italy and the USA [38, 39].”
Self-citationBlissett, R., Blissett, D. B., Levrat‐Guillen, F., Deshmukh, H., Wilmot, E. G., Ryder, R. E. J., Walton, C., & Sathyapalan, T. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002580 · Cited by 24
Ratzki‐Leewing, A., Black, J. E., Kahkoska, A. R., Ryan, B. L., Zou, G., Klar, N., Timcevska, K., & Harris, S. B. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15268 · Cited by 24 · cited 1×
“The frequency of hypoglycemic events in the model is lower than those reported in some recent studies, for example, the iNPHORM study in the USA [77] and (for persons living with T2DM) the InHypo-DM study in Canada [66].”
Self-citationBilir, S. P., Hellmund, R., Wehler, E., Li, H., Munakata, J., & Lamotte, M. (2018) · European Endocrinology · doi:10.17925/ee.2018.14.2.80 · Cited by 23 · cited 1×
“Several additional studies have found Free-Style Libre to be cost-effective in other countries, including analyses of persons living with T1DM or T2DM using MDI in the UK and Sweden [35, 73–75].”
Alshannaq, H. A., Isitt, J. J., Pollock, R. F., Norman, G. J., Cogswell, G., Lynch, P. M., & Roze, S. (2023) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2023-0075 · Cited by 21 · cited 1×
“Two further Canadian studies found the Dexcom G6 continuous glucose monitoring device to be cost-effective versus SMBG for use ) [69, 70].”
Brown, S. T., Grima, D., & Sauriol, L. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.07.019 · Cited by 20
Prato, S. D., Giorgino, F., Szafranski, K., & Poon, Y. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15703 · Cited by 19 · cited 2×
“FreeStyle Libre has also been found to be cost-effective for persons living with T2DM using basal insulin in Italy and the USA [38, 39].”
Self-citationBrixner, D. I., Ermakova, A., Xiong, Y., Sieradzan, R., Sacks, N. C., Cyr, P. L., & Taylor, S. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.12.014 · Cited by 18 · cited 4×
“The modeled population characteristics are shown in Table 1 [11, 25] and Table 2 [7, 22, 26, 27].”
InfluentialSex differences in direct healthcare costs following stroke: a population-based cohort study
Yu, A., Krahn, M. D., Austin, P. C., Rashid, M. K., Fang, J., Porter, J., Vyas, M. V., Bronskill, S. E., Smith, E. E., Swartz, R. H., et al. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-06669-w · Cited by 18 · cited 1×
“For each complication, costs were derived from Canadian real-world data identified in a targeted literature search and incorporated outpatient medical costs, rehabilitation, and medication costs [46–51].”
Sagy, I., Zimhony‐Nissim, N., Brandstaetter, E., Lipnitzki, I., Musa, H., Rosen, Y., & Barski, L. (2020) · Internal Medicine Journal · doi:10.1111/imj.14842 · Cited by 16
Szafranski, K., de Pouvourville, G., Greenberg, D., Harris, S. B., JENDLE, J. H., Shaw, J. E., Coaquira, J., Poon, Y., & Levrat‐Guillen, F. (2024) · Value in Health · doi:10.1016/j.jval.2024.01.010 · Cited by 16 · cited 6×
“This analysis used the recently published, validated, person-level microsimulation model DEDUCE [18].”
InfluentialSelf-citationRoze, S., Isitt, J. J., Smith-Palmer, J., & Lynch, P. (2021) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s304395 · Cited by 15 · cited 1×
“Two further Canadian studies found the Dexcom G6 continuous glucose monitoring device to be cost-effective versus SMBG for use ) [69, 70].”
Au, N. H., Ratzki-Leewing, A., Zou, G., Ryan, B. L., Webster-Bogaert, S., Reichert, S. M., Brown, J. B., & Harris, S. B. (2022) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.09.004 · Cited by 14 · cited 2×
“The frequency of hypoglycemic events in the model is lower than those reported in some recent studies, for example, the iNPHORM study in the USA [77] and (for persons living with T2DM) the InHypo-DM study in Canada [66].”
Self-citationAjjan, R., Bilir, S. P., Hellmund, R., & Souto, D. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01325-w · Cited by 14
Elliott, R. A., Rogers, G., Evans, M. L., Neupane, S., Rayman, G. A., Lumley, S., CRANSTON, I. C., Narendran, P., Sutton, C., Taxiarchi, V. P., et al. (2023) · Diabetic Medicine · doi:10.1111/dme.15232 · Cited by 11 · cited 1×
“Several additional studies have found Free-Style Libre to be cost-effective in other countries, including analyses of persons living with T1DM or T2DM using MDI in the UK and Sweden [35, 73–75].”
Jorissen, W., Annemans, L., Louis, N., Nilsson, A., & Willis, M. S. (2021) · Acta Clinica Belgica · doi:10.1080/17843286.2021.2015554 · Cited by 9
Return to work in heart failure patients with suspected viral myocarditis
Reibis, R. K., Kühl, U., Salzwedel, A., Rasawieh, M., Eichler, S., Wegscheider, K., & Völler, H. (2017) · SAGE Open Medicine · doi:10.1177/2050312117744978 · Cited by 7 · cited 2×
“For congestive heart failure, the proportion not returning to work was assumed to be the same as that observed in a German study of 220 people hospitalized with left heart failure and viral myocarditis [41].”
Levy, A. R., Johnston, K., Daoust, A., Ignaszewski, A. P., Fortier, J., Rogula, B., & OH, P. I. (2021) · CMAJ Open · doi:10.9778/cmajo.20200230 · Cited by 7
Miller, E. M., Roberts, G. J., Joseph, J., Nabutovsky, Y., Reyes, I. J., Souto, D., Virdi, N. S., & Hirsch, I. B. (2022) · American Journal of Medicine Open · doi:10.1016/j.ajmo.2022.100008 · Cited by 7 · cited 2×
“In addition, real-world data have shown FreeStyle Libre use to be associated with reductions in healthcare resource utilization, including all-cause hospitalization and hospitalization due to acute events [12–15].”
Cited by
Aronson, R., Abitbol, A., Bajaj, H. S., Cheng, A. Y. Y., Christopoulos, S., Harris, S. B., Jain, A. B., & Goldenberg, R. M. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70008 · Cited by 33
“A recent Canadian economic analysis using a person-level microsimulation model showed that isCGM is more cost-effective than BGM. 60 A similar analysis, modelled on the patient characteristics reported by Aronson and colleagues 49 also demonstrated greater cost-effectiveness of rtCGM over BGM for Canadian public payor…”
InfluentialSelf-citationUsing digital tools to improve diabetes care in India with continuous glucose monitoring
Kesavadev, J., Saboo, B., Chawla, M. S., Unnikrishnan, A., Dunn, T. C., & TIWASKAR, M. H. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251372290 · Cited by 8
“70, 71 Further local research is necessary to evaluate the cost-effectiveness and practical implementation of CGM technologies in the diverse Indian healthcare context.”
Bruttomesso, D., Petrie, J., Evans, M. L., Fleming, G. A., Hanaire, H. P., Holl, R. W., Sherr, J. L., Bergenstal, R. M., Heinemann, L., & Peters, A. L. (2026) · Diabetes Care · doi:10.2337/dci26-0018 · Cited by 8
Robles-Plaza, M., Peralta, F. G., Bellido, V., Ampudia‐Blasco, F. J., Carretero‐Gómez, J., Cuenca, A. M. C., de la Cuadra-Grande, A., & Mezquita‐Raya, P. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01816-6 · Cited by 6
Clinical Impact of Continuous Glucose Monitoring in Noninsulin Treated Type 2 Diabetes: A Review
Aleppo, G., Carlson, A. L., McGill, J. B., Alshannaq, H. A., Galindo, R. J., Kruger, D. F., Levy, C. J., Matuoka, J. Y., Ilham, S., Umpierrez, G. E., et al. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251414980 · Cited by 6
Metadata
- Authors
- Harris, S., Cimino, S., Nguyen, Y., Szafranski, K., & Poon, Y.
- Affiliations
- Western University (CA)
- EVERSANA (Canada) (CA)
- Abbott (Canada) (CA)
- Corresponding author
- Poon, Yeesha
- Venue
- Diabetes Therapy
- Published
- 2024-12-17
- Volume
- 16
- Issue
- 2
- Pages
- 169-186
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- PMC
- PMC11794756
- OpenAlex
- W4405458940
- Cited by
- 12
- References
- 67
- Citations by year
- 2026: 7 · 2025: 5
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Diabetes Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Abbott Diabetes Care
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- FreeStyle Libre, continuous glucose monitoring, diabetes self-management, type 1 diabetes, type 2 diabetes, self-monitoring of blood glucose, cost-effectiveness, HbA1c, hypoglycemia, diabetic ketoacidosis, quality-adjusted life years, Canadian healthcare costs, diabetes complications, insulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
